
Image Credit: Courtesy of Institute for the Advanced Study of Human Biology
Scientific Frontline: Extended "At a Glance" Summary: Decoding the Epigenome of Acute Myeloid Leukemia
The Core Concept: Acute myeloid leukemia (AML) is driven not only by gene mutations but also by its epigenome—specifically, the chromatin state that dictates which genes are active. By mapping these accessible genome regions, researchers have established a new framework that classifies AML into sixteen distinct epigenetic subgroups.
Key Distinction/Mechanism: While traditional oncological classifications rely solely on genomic mutations, this approach uses ATAC-seq technology to map the structural accessibility of chromatin across the entire genome. This reveals underlying transcription-factor networks and super-enhancer architectures that dictate disease behavior, revealing unexpected drug sensitivities completely missed by DNA sequencing alone.
Major Frameworks/Components:
- The eCHROMA AML Dataset: The largest ATAC-seq dataset ever compiled for any cancer, containing chromatin profiling from 1,563 patient samples across independent cohorts in Japan and Sweden.
- Epigenomic Subgrouping: The classification of AML into sixteen distinct, chromatin-based subgroups, each featuring unique molecular wiring, differentiation states, gene-expression profiles, and DNA methylation patterns.
- Single-Cell Multi-Omics: The integration of single-cell RNA and ATAC sequencing across more than 280,000 cells to verify that chromatin states remain tightly conserved within specific leukemic cell populations.
- 30-Gene Expression Signature: A compact, targeted diagnostic tool developed by the research team to identify high-risk, chromatin-defined subgroups using standard clinical sequencing workflows.
.png)




.jpg)


.jpg)



.jpg)
